Pozo Aledo

Researchers are evaluating the use of long-acting Cabotegravir (CAB) and Rilpivirine (RPV) in adults aged 60 years and older who are living with HIV-1 and have controlled viral levels. This study aims to confirm that the effectiveness and safety of CAB LA + RPV LA in older adults are comparable to those in younger patients. Additionally, the study monitors metabolic and liver health markers, as older adults may have more related health issues. Psychological and social well-being is also considered due to the potential impact of social stigma on this group. Participants receive an initial induction treatment with intramuscular injections of CAB LA 600 mg and RPV LA 900 mg at months 1 and 2. Following this, they receive the same injections every two months for a total duration of 24 months. This long-acting injectable treatment replaces their stable oral antiretroviral therapy regimen. Throughout the study, researchers assess viral load to confirm that HIV remains controlled with plasma HIV-1 RNA levels below 50 copies/mL. Participants are regularly monitored for metabolic and hepatic parameters, and adherence to treatment is tracked. The study also evaluates psychosocial aspects and overall safety during the two-year period to better understand treatment outcomes in this older population.